Precision Bio rises on positive FDA feedback for hepatitis B therapy study

Precision Biosciences

14/02/2024 17:37

** Shares of gene editing company Precision BioSciences
 DTIL.O  rise 7.2% to $11.97
    ** Co says the U.S. FDA has supported the design for a human
study testing its experimental gene editing therapy to treat
chronic hepatitis B
    ** DTIL plans to file a human trial application for the
therapy, PBGENE-HBV, this year
    ** PBGENE-HBV is designed to eliminate viral DNA from human
cells and could be a functional cure for chronic hepatitis B -
DTIL
    ** Hepatitis B is an infection of the liver caused by the
hepatitis B virus
    ** Including session gains, stock down ~66% in the last 12
months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))